News

18

May, 2022

RBDCOV initiates the first Phase III clinical trial of HIPRA’s Covid-19 vaccine in immunocompromised people

Tags: ,

One of the objective of RBDCOV is to test whether the vaccine can reactivate or re-generate a protective immune response against the virus The RBDCOV project, in which Penta is a partner, started a Phase III clinical trial of the Covid-19 vaccine in immunocompromised people, after the Spanish Agency for Medicines and Health Products (AEMPS) authorised it on 9 May. This clinical trial will determine whether an additional dose of HIPRA’s Covid-19 vaccine can generate an immune response in people living with immune system disorders, such as immunodeficiencies or who […]

READ MORE

15

Feb, 2022

European RBDCOV project to study HIPRA’s COVID-19 vaccine in children adolescents and immunocompromised patients

Tags: ,

Funded by the Horizon Europe programme, RBDCOV will test the efficacy, tolerability, and safety of the vaccine against the different variants of COVID-19 using a recombinant protein.                   “RBD Dimer recombinant protein vaccine against SARSCoV2” (RBDCOV) is a new Horizon Europe project led by the biotech pharmaceutical company HIPRA. Launched on 1st December, RBDCOV project objective is to test the efficacy, tolerability, and safety of the HIPRA’s recombinant Covid-19 vaccine in children (including adolescents) and immunocompromised people. The trials will last 2.5 years. […]

READ MORE

25

Jan, 2022

COVID-19 vaccines for children, adolescents and immunocompromised patients

Tags:

Penta is proud to be a partner in the Horizon Europe funded “RBD Dimer recombinant protein vaccine against SARSCoV2” (RBDCOV) project. Within the project we will be bringing our paediatric expertise and drive to improve health outcomes for children. During the project’s 2.5-year duration, RBDCOV will test the efficacy, tolerability, and safety of the Covid-19 vaccine in children, adolescents and immunocompromised people. Read the RBDCOV press release for more on the project.  

READ MORE

15

Nov, 2021

VERDI project launches

Tags: , , ,

Today we launch VERDI, a project that prioritizes women and children in the research on new coronavirus variants The University of Padua and Penta Foundation are leaders of VERDI, a new European research consortium on coronavirus in children and pregnant women. Carlo Giaquinto, Professor at University of Padova and President of Penta, together with Professor Ali Judd at University College London, will be the scientific coordinators of VERDI.   Padova, Italy – 15 November 2021 Children and pregnant women have taken a back seat during the COVID-19 pandemic. With children most likely to be the last to be […]

READ MORE

2

Jul, 2021

New data on the duration of immune protection against SARS-CoV- 2 in children

Tags:

A study published in the Pediatrics journal shows that children with mild forms of COVID-19 develop a greater and longer lasting antibody response than that of adults. The study involved 57 families affected by COVID-19, who were followed, as part of the study, by the Department of Women’s and Child Health at the University of Padua.   Padua – Italy, 2 July 2021 – Researchers from the University of Padua and the Italian health authority and research organization for animal health and food safety (IZSVe), in collaboration with Padua Hospital, Penta […]

READ MORE

28

Jun, 2021

Nuovi dati sulla durata della protezione immunitaria contro SARS-CoV-2 nei bambini

Tags:

Università degli Studi di Padova, Istituto Zooprofilattico Sperimentale delle Venezie e Penta presentano nuovi dati sulla durata della protezione immunitaria contro SARS-CoV-2 nei bambini Uno studio pubblicato in questi giorni sulla rivista “Paediatrics” dimostra che i bambini affetti da forme lievi di COVID-19 sviluppano una risposta anticorpale maggiore e più duratura di quella degli adulti. Lo studio ha coinvolto 57 famiglie venete colpite dal COVID 19 e seguite presso il Dipartimento Salute della Donna e del Bambino dell’Università di Padova.   Padova, 28 giugno 2021 – Ricercatori dell’Università degli Studi […]

READ MORE

24

Jun, 2021

Alfredo Tagarro shares his experience as a paediatrician and researcher in Spain, during the COVID-19 pandemic

Tags:

The COVID-19 pandemic has represented a unique professional and personal challenge throughout the year. Many unimaginable things happened during this frantic year, from the school closures to the confinement, and we had to adapt and think creatively. The pandemic took me back to the intensive care unit for some weeks, taking care of adults, enduring endless shifts with limited resources. Back home, we prepared and implemented research projects, again with limited resources, for children with COVID-19.  During the first months of the pandemic, we did not need to sleep much […]

READ MORE
NEWSLETTER

We would like to update you on our recent activities